Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matejka Rebolj

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 22, 2009
The challenges of organising cervical screening programmes in the 15 old member states of the European UnionMarc Arbyn, Matejka Rebolj, Inge M C M De Kok, et al.
International Journal of Cancer|June 15, 2007
Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategiesMatejka Rebolj, Aagje G Bais, Marjolein van Ballegooijen, et al.
Acta Oncologica (Stockholm, Sweden)|December 16, 2014
Cervical cancer screening in the Faroe IslandsTurið Hammer, Elsebeth Lynge, Gisela W Djurhuus, et al.
British Journal of Cancer|August 15, 2019
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilotMatejka Rebolj, Adam R Brentnall, Christopher Mathews, et al.
International Journal of Cancer|February 15, 2017
Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platformsJanni Uyen Hoa Lam, Matejka Rebolj, Ditte Møller Ejegod, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2009
Cervical cancer screening policies and coverage in EuropeAhti Anttila, Lawrence von Karsa, Auni Aasmaa, et al.
The Lancet. Public Health|May 3, 2021
Cervical screening during the COVID-19 pandemic: optimising recovery strategiesAlejandra Castanon, Matejka Rebolj, Emily Annika Burger, et al.
BMJ (Clinical Research Ed.)|October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyJoakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
BMJ (Clinical Research Ed.)|February 16, 2017
Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based studyKirsten Rozemeijer, Steffie K Naber, Corine Penning, et al.
Preventive Medicine|May 24, 2021
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysisMegan A Smith, Emily A Burger, Alejandra Castanon, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|August 22, 2009
The challenges of organising cervical screening programmes in the 15 old member states of the European UnionMarc Arbyn, Matejka Rebolj, Inge M C M De Kok, et al.
International Journal of Cancer|June 15, 2007
Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategiesMatejka Rebolj, Aagje G Bais, Marjolein van Ballegooijen, et al.
Acta Oncologica (Stockholm, Sweden)|December 16, 2014
Cervical cancer screening in the Faroe IslandsTurið Hammer, Elsebeth Lynge, Gisela W Djurhuus, et al.
British Journal of Cancer|August 15, 2019
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilotMatejka Rebolj, Adam R Brentnall, Christopher Mathews, et al.
International Journal of Cancer|February 15, 2017
Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platformsJanni Uyen Hoa Lam, Matejka Rebolj, Ditte Møller Ejegod, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2009
Cervical cancer screening policies and coverage in EuropeAhti Anttila, Lawrence von Karsa, Auni Aasmaa, et al.
The Lancet. Public Health|May 3, 2021
Cervical screening during the COVID-19 pandemic: optimising recovery strategiesAlejandra Castanon, Matejka Rebolj, Emily Annika Burger, et al.
BMJ (Clinical Research Ed.)|October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyJoakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
BMJ (Clinical Research Ed.)|February 16, 2017
Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based studyKirsten Rozemeijer, Steffie K Naber, Corine Penning, et al.
Preventive Medicine|May 24, 2021
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysisMegan A Smith, Emily A Burger, Alejandra Castanon, et al.
Pageof 9